article thumbnail

Inferring human genomes at a fraction of the cost promises to boost biomedical research

Scienmag

To discover these associations, researchers need to compare the genomes of many individuals at millions of genetic locations or markers, and therefore require cost-effective genotyping technologies. A new statistical method, developed […].

Genome 57
article thumbnail

Why early participant engagement is now a top priority in genetic disease research

pharmaphorum

However, the Resilience Project’s scientists had used genomic data originally collected for other studies and, due to limitations in the original studies’ informed consent policies and a lack of infrastructure to recontact participants, none of the 13 individuals could be contacted with follow-up questions or requests.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cancer, genomics and personalised medicine: Modelling the future of oncology

pharmaphorum

Personalised medicine in practice – where are we now in cancer? How the shift towards cancer as a phenotype/genotype is being applied in clinical trials and how they are run •What are co-clinical trials and why could they hold the key to answering unmet need in cancer treatment and beyond into broader drug development?

article thumbnail

FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review

The Pharma Data

Decision Regarding Slick-Haired Cattle is Agency’s First Enforcement Discretion Decision for an Intentional Genomic Alteration in an Animal for Food Use. The IGA results in the equivalent genotype (genetic make-up) and short-hair coat trait seen in some conventionally bred cattle, known as a “slick” coat. Today, the U.S.

Genome 52
article thumbnail

Endometriosis partners to discover personalised treatments

Drug Discovery World

The OXEGENE dataset contains anonymised genotype data including disease stage and infertility status, from 1,000 surgically confirmed patients. We hope that the analysis of our data will lead to the development of precision medicines to improve the lives of patients.”

article thumbnail

Supercharging AI-drug discovery with strategic multiomic biobanks 

Drug Discovery World

In anticipation of the long-awaited personalised medicine revolution, many different types of biobanks have emerged to catalogue samples. Towards personalised medicine for populations From my vantage point, we are still in the early days of understanding the value of biobanked samples and AI-models in designing new drugs.

article thumbnail

Can genetic data be a magic bullet for drug R&D?

pharmaphorum

The cost of testing per human genome in 2006 was approximately $14 million , and in less than two decades, an average consumer-purchased genetic test costs $100. The same is becoming true for the healthcare industry, and one of the first major breakthroughs in the area was the 100,000 Genomes Project.